Steroids in COPD: still up in the air?: Fig. 1—
Authors:
- D. D. SinDSD. D. Sin
- S. F. P. ManSMS. F. P. Man
Open Access
- 1 May 2010
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 35 (5) , 949-951
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Modeling the effects of pharmaceutical marketingMarketing Letters, 2009
- Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbationsRespiratory Medicine, 2008
- COPD as a Lung Disease with Systemic Consequences – Clinical Impact, Mechanisms, and Potential for Early InterventionCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2008
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2007
- Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax, 2005
- Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylaseThe Lancet, 2004
- Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2000
- Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statementThe Lancet, 1999
- Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue SmokingNew England Journal of Medicine, 1999
- Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 1999